OR WAIT null SECS
Paragon BioTeck has received FDA approval of its phenylephrine hydrochloride ophthalmic solution, USP 2.5% and 10%, to dilate the pupil.
Portland-Paragon BioTeck has received FDA approval of its phenylephrine hydrochloride ophthalmic solution, USP 2.5% and 10%, to dilate the pupil.
According to the company, there is no longer a need to continue using unapproved versions of the solution as Paragon’s newly FDA-approved alpha-1 adrenergic receptor agonist is readily available through Bausch + Lomb.
“Paragon is committed to working proactively with the FDA in an effort to prevent disrupting supply of this and future drugs that play a vital role in managing ocular health,” said Patrick H. Witham, president and chief executive officer of Paragon.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.